Methods and compositions for chimeric antigen receptor targeting cancer cells
AssigneeThe University of North Carolina at Chapel Hill
InventorsGianpietro Dotti, Chuang Sun, Peishun Shou, Yang Xu
Life of this patent
Estimating the term…
Abstract
The present invention provides chimeric antigen receptors (CAR) and methods of use in the treatment of diseases and disorders.
Claims33
A chimeric antigen receptor (CAR) comprising a hinge region, a transmembrane domain, a CD3 domain, an scFv, a CD28 costimulatory molecule, and an FKBP-rapamycin binding domain (FRB), wherein the scFv binds to TSHR, CD19, CD123, CD22, CD30, CD171, CS-1, CLL-1, CD33, EGFRvIII, GD2, GD3, BCMA, Tn Ag, PSMA, ROR1, FLT3, FAP, TAG72, CD38, CD44v6, CEA, EPCAM, B7H3, KIT, IL-13Ra2, Mesothelin, IL-11Ra, PSCA, PRSS21, VEGFR2, LewisY, CD24, PDGFR-β, SSEA-4, CD20, FRα, ERBB2(Her2/neu), MUC1, EGFR, NCAM, Prostase, PAP, ELF2M, EphB2, IGF-I receptor, CAIX, LMP2, gp100, bcr-abl, tyrosinase, EphA2, GM1, sLe, GM3, TGSS, HMWMAA, FRβ, TEM1/CD248, TEM7R, CLDN6, GPRCSD, CXORF61, CD97, CD179a, ALK, PSA, PLAC1, GloboH, NY-BR-1, UPK2, HAVCR1, ADRB3, PANX3, GPR20, LY6K, OR51E2, TARP, WT1, NY-ESO-1, LAGE-1a, MAGE-AL legumain, HPV E6, E7, MAGE A1, ETV6-AML, Sp17, XAGE1, Tie 2, MAD-CT-1, MAD-CT-2, FRA1, p53, p53 mutants, prostein, survivin, PCTA-1/Galectin8, MelanA/MART1, Ras, hTERT, ML-IAP, ER, TMPRSS2 ETS fusion gene, NA17, PAX3, AR, cyclin B1, MYCN, RhoC, TRP-2, CYP1B1, BORIS, SART3, PAX5, OY-TES1, LCK, AKAP-4, SSX2, RAGE-1, RU1, RU2, CEA, hsp70-2, CD79a, CD79b, CD72, LAIR1, FCAR, LILRA2, CD300LF, CLEC12A, BST2, EMR2, LY75, GPC3, CLN18.2, CLN6, FCRL5, IGLL1, or any variant thereof.
(canceled)
(canceled)
6-7. (canceled)
A polypeptide comprising an FKBP sequence linked to SHP1.
A composition comprising:
- a chimeric antigen receptor (CAR) comprising a 4-1BB costimulatory molecule;
- and
- a lymphocyte-specific protein tyrosine kinase (LCK) protein, optionally wherein the LCK comprises a detectable moiety.
18-21. (canceled)
A vector comprising:
- a nucleic acid molecule encoding a CAR comprising a 4-1BB costimulatory molecule;
- and
- a second nucleic acid molecule comprising an LCK open reading frame, optionally wherein the LCK ORF encodes a detectable moiety.
24-28. (canceled)
(canceled)
36-39. (canceled)
41-42. (canceled)
45-46. (canceled)
Dependencies are inferred from the claim text.